A multicenter, randomized controlled study to evaluate the efficacy and safety of Carmell Therapeutics' Bone Healing Accelerant as an alternative to autologous bone grafting to promote bony fusion during foot and ankle fusion surgery
Latest Information Update: 06 Dec 2023
At a glance
- Drugs CT 101-carmell corporation (Primary)
- Indications Bone disorders; Fracture
- Focus Therapeutic Use
Most Recent Events
- 04 Jan 2023 According to a Carmell Therapeutics media release, the company expect to initiate this trial in Q3, 2023.
- 25 Nov 2022 New trial record